geopolitics-00535
A hemodialysis unit at Moscow's Clinical Hospital No 52 treating COVID-19 patients, patients with suspected coronavirus and patients with viral community-acquired pneumonia. Vladimir Gerdo/TASS

MOSCOW, October 21. /TASS/. Five Russian companies are working actively on the production of the Sputnik V vaccine against the coronavirus, Head of the Russian Direct Investment Fund (RDIF) Kirill Dmitriev said in an interview with the Russia-1 TV channel on Wednesday.

The press service specified that the Binnopharm, R-Pharm, Biocad, Generium companies and the Gamaleya Center will produce the vaccine.

“Now there are already five companies that are already planning to produce the vaccine in the near future and accordingly they are working very actively on the sharp increase in capacities, I think, we’ll see it next month and will see even more in December,” he said.

On August 11, Russia became the first worldwide to register the vaccine against the coronavirus which was named Sputnik V. The preparation was developed by the Gamaleya National Research Center for Epidemiology and Microbiology of the Russian Healthcare Ministry and passed clinical trials in June – July. It is based on a known platform previously used for other vaccines. The Healthcare Ministry noted that the experience of use of similar preparations shows that they are capable of providing a lengthy immunity of up to two years.